Shin Egawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shin Egawa has a total of 238 co-authors. Here are the top co-authors by number of shared publications:
- Takahiro Kimura
Department of Urology The Jikei University School of Medicine Tokyo Japan
12 shared publications - Shahrokh Francois Shariat
Department of Urology, Medical University of Vienna, Vienna, Austria
10 shared publications - Keiichiro Mori
Department of Urology The Jikei University School of Medicine Tokyo Japan
8 shared publications - Hiroshi Sasaki
Department of Urology The Jikei University School of Medicine Tokyo Japan
7 shared publications - Fumihiko Urabe
Department of Urology The Jikei University School of Medicine Tokyo Japan
6 shared publications - Benjamin Pradere
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
5 shared publications
Latest Publications
- Open Access
- 14 September 2022
- Published by Springer Nature in BMC Urology
- Vol. 22 (1) , 1-10
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
The effect of enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade, which represents a patient profile similar to real-world clinical practice in Japan, remains unknown. Therefore, we investigate the efficacy and safety of enzalutamide after combined androgen blockade for recurrence following radical treatment in Japanese patients with non-metastatic castration-resistant prostate cancer. We analyzed 66 patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical prostatectomy or radiation therapy who were prospectively enrolled from October 2015 to March 2018. They received enzalutamide 160 mg orally once daily until the protocol treatment discontinuation criteria were met. The primary endpoint was prostate-specific antigen-progression-free survival, defined as the time from enrollment to prostate-specific antigen-based progression or death from any cause. The secondary endpoints included overall survival, progression-free survival, metastasis-free survival, time to prostate-specific antigen progression, prostate-specific antigen response rate, chemotherapy-free survival, and safety assessment. The median observation period was 27.3 months. The median prostate-specific antigen-progression-free survival was 35.0 months (95% confidence interval, 17.5 to not reached). The median overall survival, median progression-free survival, median metastasis-free survival, and chemotherapy-free survival were not reached, with the corresponding 2-year rates being 91.6%, 67.1%, 72.4%, and 85.8%, respectively. The 50% prostate-specific antigen response rate was 88.9%, with the median time being 2.8 months. In total, 42.2% of the patients experienced adverse events, with malaise being the most common. Enzalutamide effectively manages non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment. Trial registration: UMIN000018964, CRB6180007.
- 14 September 2022
- Published by Springer Nature in BMC Urology
- Vol. 22 (1) , 1-10
Open AccessEnzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
The effect of enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade, which represents a patient profile similar to real-world clinical practice in Japan, remains unknown. Therefore, we investigate the efficacy and safety of enzalutamide after combined androgen blockade for recurrence following radical treatment in Japanese patients with non-metastatic castration-resistant prostate cancer. We analyzed 66 patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical prostatectomy or radiation therapy who were prospectively enrolled from October 2015 to March 2018. They received enzalutamide 160 mg orally once daily until the protocol treatment discontinuation criteria were met. The primary endpoint was prostate-specific antigen-progression-free survival, defined as the time from enrollment to prostate-specific antigen-based progression or death from any cause. The secondary endpoints included overall survival, progression-free survival, metastasis-free survival, time to prostate-specific antigen progression, prostate-specific antigen response rate, chemotherapy-free survival, and safety assessment. The median observation period was 27.3 months. The median prostate-specific antigen-progression-free survival was 35.0 months (95% confidence interval, 17.5 to not reached). The median overall survival, median progression-free survival, median metastasis-free survival, and chemotherapy-free survival were not reached, with the corresponding 2-year rates being 91.6%, 67.1%, 72.4%, and 85.8%, respectively. The 50% prostate-specific antigen response rate was 88.9%, with the median time being 2.8 months. In total, 42.2% of the patients experienced adverse events, with malaise being the most common. Enzalutamide effectively manages non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment. Trial registration: UMIN000018964, CRB6180007.
- Open Access
- 1 July 2022
- Published by Elsevier in European Urology Focus
- Vol. 8 (4) , 972-979
The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy
- 1 July 2022
- Published by Elsevier in European Urology Focus
- Vol. 8 (4) , 972-979
Open AccessThe Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy
- 25 April 2022
- Published by Taylor & Francis in Immunotherapy
- Vol. 14 (9) , 709-725
Hematological Prognosticators in Metastatic Renal Cell Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis
Aim: We aimed to assess the prognostic value of pretreatment hematological biomarkers in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). Metho... Plain language summary Identifying the predictive/prognostic factors that can be applied to daily clinical practice is mandatory to facilitate the use of immune checkpoint inhibitors. Some pretreat...
- 25 April 2022
- Published by Taylor & Francis in Immunotherapy
- Vol. 14 (9) , 709-725
Hematological Prognosticators in Metastatic Renal Cell Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis
Aim: We aimed to assess the prognostic value of pretreatment hematological biomarkers in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). Metho... Plain language summary Identifying the predictive/prognostic factors that can be applied to daily clinical practice is mandatory to facilitate the use of immune checkpoint inhibitors. Some pretreat...
- Open Access
- 12 April 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (8) , 5317-5318
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
- 12 April 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (8) , 5317-5318
Open AccessASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
- 25 March 2022
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 40 (7) , 344.e11-344.e17
Prognostic value of the fluctuation in the neutrophil–lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma
- 25 March 2022
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 40 (7) , 344.e11-344.e17
Prognostic value of the fluctuation in the neutrophil–lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma
- Open Access
- 3 March 2022
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 27 (4) , 827
Correction to: The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study
- 3 March 2022
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 27 (4) , 827
Open AccessCorrection to: The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study
- 1 March 2022
- Vol. 68 (3) , 87-90
[Laparoscopic Radical Cystectomy with Ileal Neobladder for Metachronous Bladder Cancer Following Laparoscopic Radical Prostatectomy : A Case Report].
A 67-year-old man presented with gross hematuria. The patient underwent laparoscopic radical prostatectomy for localized prostate cancer 8 years ago. Metachronous bladder cancer (pT1, high-grade and pTis) was diagnosed by transurethral resection. Laparoscopic radical cystectomy and construction of an ileal neobladder were performed. During the operation, mild adhesion was observed between the bladder and rectum ; however, there were no intraoperative complications. The patient had dysuria 2 months postoperatively, and neovesical-urethral anastomotic stricture was revealed by cystoscopy. We performed transurethral incision, and the patient voided properly except for mild incontinence. There was no evidence of recurrence 4 years after the operation.
- 1 March 2022
- Vol. 68 (3) , 87-90
[Laparoscopic Radical Cystectomy with Ileal Neobladder for Metachronous Bladder Cancer Following Laparoscopic Radical Prostatectomy : A Case Report].
A 67-year-old man presented with gross hematuria. The patient underwent laparoscopic radical prostatectomy for localized prostate cancer 8 years ago. Metachronous bladder cancer (pT1, high-grade and pTis) was diagnosed by transurethral resection. Laparoscopic radical cystectomy and construction of an ileal neobladder were performed. During the operation, mild adhesion was observed between the bladder and rectum ; however, there were no intraoperative complications. The patient had dysuria 2 months postoperatively, and neovesical-urethral anastomotic stricture was revealed by cystoscopy. We performed transurethral incision, and the patient voided properly except for mild incontinence. There was no evidence of recurrence 4 years after the operation.
- 20 February 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (6_suppl) , 280
Comparison of the medical costs between active surveillance and other treatment for early prostate cancer in Japan: From the data of PRIAS JAPAN study.
280 Background: As the number of prostate cancer patients increases, the cost of treatment is becoming an urgent issue. To compare the costs between active surveillance, robot-assisted laparoscopic prostatectomy (RALP), Brachytherapy (BT), Intensity Modulated Radiation Therapy (IMRT), and Androgen deprivation therapy(ADT). Methods: The costs of protocol biopsies in the first year of AS performed between January 2010 and June 2020, and the treatment costs of RALP, BT, and IMRT performed between May 2019 and June 2020 at Kagawa university hospital were analyzed. The cost of ADT was assumed to be the cost of the LH-RH analog over 5 years. The inpatient treatment cost for each treatment was calculated from our DPC data, and for IMRT, the treatment cost was calculated by the outpatient cost at the time of irradiation. AS-eligible patients were defined as less than 74 years old, less than T2, less than GS6, and less than two positive cores. We estimated the total number of AS-eligible patients in Japan based on the data of the J-CAP study and the data of cancer statistics in 2017 and estimated the total treatment cost of AS-eligible patients based on the data of treatment breakdown of T1/T2 patients in the J-CAP study. In addition, we used the data from PRIAS-JAPAN to calculate the AS continuation rate, protocol biopsy acceptance rate, and the breakdown of secondary treatments. We simulated the 5-year treatment cost for AS patients using the system. Results: The median treatment costs for AS (n = 45), RALP (n = 68), BT (n = 27), and IMRT (n = 44), and ADT were US$1.24 thousand, US$ 14.6 thousand, US$14.8 thousand, US$ 12.9 thousand, and US$8.16, respectively. The number of AS-eligible patients in Japan was estimated to be 5414, and the total cost of AS, RALP, BT, IMRT, HT, and ADT over 5 years was estimated to be US$3.07 million, US$34.8 million, US$8.46 million, US$11.09 million, and US$14.05 million, respectively. If 50% and 100% of the patients in each treatment group chose AS as their first treatment, the total cost of treatment would be reduced by US$18.6 million and US$38.5 million, respectively. Conclusions: The prevalence of AS will contribute to reducing the cost of prostate cancer treatment.
- 20 February 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (6_suppl) , 280
Comparison of the medical costs between active surveillance and other treatment for early prostate cancer in Japan: From the data of PRIAS JAPAN study.
280 Background: As the number of prostate cancer patients increases, the cost of treatment is becoming an urgent issue. To compare the costs between active surveillance, robot-assisted laparoscopic prostatectomy (RALP), Brachytherapy (BT), Intensity Modulated Radiation Therapy (IMRT), and Androgen deprivation therapy(ADT). Methods: The costs of protocol biopsies in the first year of AS performed between January 2010 and June 2020, and the treatment costs of RALP, BT, and IMRT performed between May 2019 and June 2020 at Kagawa university hospital were analyzed. The cost of ADT was assumed to be the cost of the LH-RH analog over 5 years. The inpatient treatment cost for each treatment was calculated from our DPC data, and for IMRT, the treatment cost was calculated by the outpatient cost at the time of irradiation. AS-eligible patients were defined as less than 74 years old, less than T2, less than GS6, and less than two positive cores. We estimated the total number of AS-eligible patients in Japan based on the data of the J-CAP study and the data of cancer statistics in 2017 and estimated the total treatment cost of AS-eligible patients based on the data of treatment breakdown of T1/T2 patients in the J-CAP study. In addition, we used the data from PRIAS-JAPAN to calculate the AS continuation rate, protocol biopsy acceptance rate, and the breakdown of secondary treatments. We simulated the 5-year treatment cost for AS patients using the system. Results: The median treatment costs for AS (n = 45), RALP (n = 68), BT (n = 27), and IMRT (n = 44), and ADT were US$1.24 thousand, US$ 14.6 thousand, US$14.8 thousand, US$ 12.9 thousand, and US$8.16, respectively. The number of AS-eligible patients in Japan was estimated to be 5414, and the total cost of AS, RALP, BT, IMRT, HT, and ADT over 5 years was estimated to be US$3.07 million, US$34.8 million, US$8.46 million, US$11.09 million, and US$14.05 million, respectively. If 50% and 100% of the patients in each treatment group chose AS as their first treatment, the total cost of treatment would be reduced by US$18.6 million and US$38.5 million, respectively. Conclusions: The prevalence of AS will contribute to reducing the cost of prostate cancer treatment.
- 16 December 2021
- Published by Wiley in The Prostate
- Vol. 82 (4) , 433-441
Clinical significance of unfavorable findings in intermediate‐risk prostate cancer patients for predicting treatment outcomes after contemporary, dose‐escalated multimodal radiotherapy
Purpose: Few studies have documented the long‐term oncological outcomes of favorable and unfavorable intermediate‐risk (IR) prostate cancer patients treated via contemporary high‐dose irradiation. We analyzed the ultimate clinical outcomes of such patients using the current risk sub‐stratification schema.Patients and Methods: We included 693 patients with localized IR prostate cancer treated via low‐dose‐rate brachytherapy (LDR‐BT) with or without external beam radiation (EBRT) and with or without androgen‐deprivation therapy (ADT) in a single institution. Treatment outcomes (biochemical recurrence‐free survival [BCRFS] and clinical progression‐free survival [CPFS]) were compared according to the numbers of unfavorable findings.Results: Out of the 693 IR patients, 292 (42.1%) exhibited favorable disease; the remaining 401 (57.9%) exhibited unfavorable disease. Compared with favorable IR status, unfavorable IR status was associated with shorter BCRFS and CPFS (p < 0.001 and p < 0.001, respectively). Patients with two to three unfavorable factors experienced the worst oncological outcomes (p < 0.001 and p < 0.001). Although patients with one or no unfavorable factors responded similarly to LDR‐BT monotherapy, this treatment modality was insufficient for preventing biochemical and clinical progression in patients with multiple unfavorable findings.Conclusion: Long‐term treatment outcomes indicate that patients with IR disease scheduled for LDR‐BT should undergo multimodal irradiation if they exhibit two or more unfavorable factors at diagnosis.
- 16 December 2021
- Published by Wiley in The Prostate
- Vol. 82 (4) , 433-441
Clinical significance of unfavorable findings in intermediate‐risk prostate cancer patients for predicting treatment outcomes after contemporary, dose‐escalated multimodal radiotherapy
Purpose: Few studies have documented the long‐term oncological outcomes of favorable and unfavorable intermediate‐risk (IR) prostate cancer patients treated via contemporary high‐dose irradiation. We analyzed the ultimate clinical outcomes of such patients using the current risk sub‐stratification schema.Patients and Methods: We included 693 patients with localized IR prostate cancer treated via low‐dose‐rate brachytherapy (LDR‐BT) with or without external beam radiation (EBRT) and with or without androgen‐deprivation therapy (ADT) in a single institution. Treatment outcomes (biochemical recurrence‐free survival [BCRFS] and clinical progression‐free survival [CPFS]) were compared according to the numbers of unfavorable findings.Results: Out of the 693 IR patients, 292 (42.1%) exhibited favorable disease; the remaining 401 (57.9%) exhibited unfavorable disease. Compared with favorable IR status, unfavorable IR status was associated with shorter BCRFS and CPFS (p < 0.001 and p < 0.001, respectively). Patients with two to three unfavorable factors experienced the worst oncological outcomes (p < 0.001 and p < 0.001). Although patients with one or no unfavorable factors responded similarly to LDR‐BT monotherapy, this treatment modality was insufficient for preventing biochemical and clinical progression in patients with multiple unfavorable findings.Conclusion: Long‐term treatment outcomes indicate that patients with IR disease scheduled for LDR‐BT should undergo multimodal irradiation if they exhibit two or more unfavorable factors at diagnosis.